RecruitingNCT05739591

Long-term Safety and Efficacy of GBG Study Participants

Registry for Long-term Follow-up of Safety and Efficacy Parameters of GBG Study Participants

Sponsor

GBG Forschungs GmbH

Enrollment

400 participants

Start Date

Oct 12, 2022

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

The ETERNITY study is an international, multicenter, observational study that aims to follow up patients who have participated in a GBG trial for early breast cancer, even after the study has officially ended, in order to collect long-term data on survival, late or delayed adverse events, in addition to information related to pregnancy, fertility and other parameters impacting quality of life.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This long-term follow-up study is collecting safety and effectiveness data from people who previously participated in a breast cancer clinical trial run by the German Breast Group (GBG). Rather than testing a new treatment, this study tracks what happens to these patients over the long term. **You may be eligible if...** - You previously received treatment as part of a GBG clinical trial for early-stage breast cancer - You are willing to provide written consent for ongoing data and tissue collection **You may NOT be eligible if...** - Your previous clinical trial was not run by GBG - You participated in a GBG trial for advanced or metastatic (spread) breast cancer rather than early breast cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(23)

Universitätsklinikum Innsbruck, Klinische Abteilung f. Gynäkologie und Geburt

Innsbruck, Triol, Austria

Klinikum Wels-Grieskirchen GmbH

Wels, Upper Austria, Austria

MedUni Graz - Med. Universitätsklinik, Klinische Abteilung für Onkologie

Graz, Austria

MedUni Graz - Universitätsklinik für Frauenheilkunde und Geburtshilfe

Graz, Austria

Ordensklinikum Linz GmbH - BHS

Linz, Austria

LKH Salzburg - PMU

Salzburg, Austria

Medical University of Vienna, Brustambulanz AKH Wien

Vienna, Austria

Klinik Hietzing Wien

Vienna, Austria

Hospital Reina Sofia, Servicio Oncología Planta sotano

Córdoba, Andalusia, Spain

Hospital Universitario Basurto, Servicio de Oncología médica

Bilbao, Basque Country, Spain

Hospital Universitario de Canarias

Santa Cruz de Tenerife, Canary Islands, Spain

Hospital Germans Trias i Pujol

Badalona, Catalonia, Spain

Hospital Universitari Vall d´Hebron, Servicio de Oncologia Medica

Barcelona, Catalonia, Spain

Hospital Clinic i Provincial de Barcelona

Barcelona, Catalonia, Spain

H. Santa Creu I Sant Pau

Barcelona, Catalonia, Spain

Fundació IRB Lleida, Oncología, Unidad de ensayos clínicos

Lleida, Catalonia, Spain

Hospital Parc Tauli

Sabadell, Catalonia, Spain

Hospital San Pedro de Alcantara

Cáceres, Extremadura, Spain

Hospital Universitario Ramon y Cajal, Servicio de Oncología Médica/ Oficina de Ensayos Clínicos

Madrid, Madrid, Spain

Hospital Universitario Clínico San Carlos, Servicio de Oncología Médica

Madrid, Madrid, Spain

Fundación Instituto Valenciano de Oncología (IVO)

Valencia, Valencia, Spain

Hospital Universitario Infanta Cristina, Centro de Investigacíon Clinica e Área de Sal

Badajoz, Spain

Hospital Universitario Virgen der Rocio

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05739591

Related Trials

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT040386191 location

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

NCT07619534

Long-term Safety and Efficacy of GBG Study Participants

Conditions

Summary

Eligibility

Plain Language Summary

Locations(23)

Related Trials

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

Pulsed Electric Field Ablation for Metastatic Breast Cancer

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies